Progression of prodromal motor and non-motor symptoms in the premotor phase study - 2-year follow-up data

2017 ◽  
Vol 24 (11) ◽  
pp. 1369-1374 ◽  
Author(s):  
I. Liepelt-Scarfone ◽  
B. Brändle ◽  
R. Yilmaz ◽  
K. Gauss ◽  
E. Schaeffer ◽  
...  
Keyword(s):  
Motor Symptoms ◽  
Phase Study ◽  
Premotor Phase ◽  
Non Motor Symptoms

Gender differences in non-motor symptoms in early Parkinson's disease: A 2-years follow-up study on previously untreated patients

2014 ◽  
Vol 20 (8) ◽  
pp. 850-854 ◽  
Author(s):  
Marina Picillo ◽  
Roberto Erro ◽  
Marianna Amboni ◽  
Katia Longo ◽  
Carmine Vitale ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Gender Differences ◽  
Parkinson's Disease ◽  
Motor Symptoms ◽  
Follow Up Study ◽  
Non Motor Symptoms ◽  
Early Parkinson’S Disease

P132 DeNoPa Kassel – A long-term follow-up study on biomarkers and non-motor symptoms for Parkinson disease

Basal Ganglia ◽  
2011 ◽  
Vol 1 (1) ◽  
pp. 30
Author(s):  
B. Mollenhauer ◽  
E. Trautmann ◽  
M. Schaumburg ◽  
T. Wicke ◽  
B. Otte ◽  
...  
Keyword(s):  
Parkinson Disease ◽  
Motor Symptoms ◽  
Follow Up Study ◽  
Long Term Follow Up ◽  
Non Motor Symptoms

scholarly journals Non-motor symptoms in premotor phase of Parkinson disease

2013 ◽  
Vol 53 (11) ◽  
pp. 974-976 ◽  
Author(s):  
Kazushi Takahashi
Keyword(s):  
Parkinson Disease ◽  
Motor Symptoms ◽  
Premotor Phase ◽  
Non Motor Symptoms

scholarly journals Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age

2020 ◽  
Author(s):  
Francesca Morgante ◽  
Valentina Oppo ◽  
Margherita Fabbri ◽  
Enrica Olivola ◽  
Chiara Sorbera ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
Control Group ◽  
Motor Symptoms ◽  
Study Visit ◽  
Non Motor Symptoms

Abstract Objectives Levodopa–Carbidopa Intrajejunal gel (LCIG) infusion is an effective intervention for people with advanced Parkinson’s disease (PD). Although age may not be a limiting factor for LCIG implant, no data are available on late elderly PD (LE-PD) subjects. In this cross-sectional, we aimed to demonstrate if older age may impact on quality of life (QoL), motor and non-motor symptoms severity, and profile of side effects in PD treated with LCIG. Methods Out of 512 PD subjects treated with LCIG at 9 Italian PD centers, we selected 25 LE-PD defined as age ≥ 80 years at last follow-up who were available to attend the study visit. Twenty-five PD patients (Control-PD, defined as age < 75 years at last follow-up) matched to LE-PD by disease and LCIG duration served as control group. The following motor and non-motor variables were ascertained: quality of life (PDQ-8), time spent in ON, wearing-off Questionnaire, Unified PD Rating Scale, freezing of gait questionnaire, Parkinson’s disease sleep scale-2, Non Motor Symptoms Scale (NMSS), and MOCA. Results No statistically significant differences were found between LE-PD and Control-PD on PDQ-8 and several motor and non-motor variables. LE-PD had less frequent and milder impulsive–compulsive behaviors and milder dyskinesia. At multivariable regression, worse quality of life was associated with UPDRS-III and NMSS scores but not to age at study visit and age at LICG implant. Rate of adverse effects was similar in both groups. Drop-out rate calculated in the whole PD cohort was comparable between the two groups. Conclusion Our data provide evidence that valuable LCIG infusion might be achieved in late elderly PD.

scholarly journals The severity progression of non-motor symptoms in Parkinson’s disease: a 6-year longitudinal study in Taiwanese patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yi-Chieh Chen ◽  
Rou-Shayn Chen ◽  
Yi-Hsin Weng ◽  
Ying-Zu Huang ◽  
Chiung Chu Chen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Longitudinal Study ◽  
Disease Duration ◽  
Rating Scale ◽  
Medical Center ◽  
Motor Symptoms ◽  
Disease Rating ◽  
Non Motor Symptoms

AbstractNonmotor symptoms (NMSs) cause major burden in patients with Parkinson’s disease (PD). Previous NMSs progression studies mostly focused on the prevalence. We conducted a longitudinal study to identify the progression pattern by the severity. PD patients recruited from the outpatient clinics of a tertiary medical center were evaluated by the Unified Parkinson's Disease Rating Scale and Non-Motor Symptoms Scale (NMSS). A retrospective study with three-step analysis was performed. Step 1, the NMSs severity was compared among patients stratified by disease duration every 2 years up to 10 years. Step 2, patients with repeated tests in 2 years were categorized into 4 groups by the diseased duration of every 5 years. Step 3, the NMSS score changes in 6 years follow-up were determined, and the dosage of anti-PD drugs was compared to the NMSs severity changes. 676 patients completed the step 1 analysis, which showed a trend of NMSs worsening but not significant until the disease duration longer than 4–6 years. Furthermore, the severity did not change between repeated evaluations in 2 years in all patients. The progression became apparent after 6 years. Individual symptoms had different progression patterns and the increment of medications was independent to NMSs evolution. We demonstrated the NMSs severity progression in Taiwanese PD patients and the independence of the medications and NMSs progression.

Progression of non-motor symptoms in Parkinson's disease among different age populations: A two-year follow-up study

2016 ◽  
Vol 360 ◽  
pp. 72-77 ◽  
Author(s):  
Ruwei Ou ◽  
Jing Yang ◽  
Bei Cao ◽  
Qianqian Wei ◽  
Ke Chen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Symptoms ◽  
Follow Up Study ◽  
Non Motor Symptoms

scholarly journals Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson’s disease patients for the identification and validation of biomarkers for Parkinson’s disease subtypes, progression and pathophysiology

BMC Neurology ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Jeffrey M. Boertien ◽  
◽  
Sygrid van der Zee ◽  
Asterios Chrysou ◽  
Marleen J. J. Gerritsen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cohort Study ◽  
Pet Imaging ◽  
De Novo ◽  
Gastrointestinal Function ◽  
Motor Symptoms ◽  
Treatment Naïve ◽  
Non Motor Symptoms

Abstract Background Parkinson’s Disease (PD) is a heterogeneous, progressive neurodegenerative disorder which is characterized by a variety of motor and non-motor symptoms. To date, no disease modifying treatment for PD exists. Here, the study protocol of the Dutch Parkinson Cohort (DUPARC) is described. DUPARC is a longitudinal cohort study aimed at deeply phenotyping de novo PD patients who are treatment-naïve at baseline, to discover and validate biomarkers for PD progression, subtypes and pathophysiology. Methods/design DUPARC is a prospective cohort study in which 150 de novo PD subjects will be recruited through a collaborative network of PD treating neurologists in the northern part of the Netherlands (Parkinson Platform Northern Netherlands, PPNN). Participants will receive follow-up assessments after 1 year and 3 years, with the intention of an extended follow-up with 3 year intervals. Subjects are extensively characterized to primarily assess objectives within three major domains of PD: cognition, gastrointestinal function and vision. This includes brain magnetic resonance imaging (MRI); brain cholinergic PET-imaging with fluoroethoxybenzovesamicol (FEOBV-PET); brain dopaminergic PET-imaging with fluorodopa (FDOPA-PET); detailed neuropsychological assessments, covering all cognitive domains; gut microbiome composition; intestinal wall permeability; optical coherence tomography (OCT); genotyping; motor and non-motor symptoms; overall clinical status and lifestyle factors, including a dietary assessment; storage of blood and feces for additional analyses of inflammation and metabolic parameters. Since the start of the inclusion, at the end of 2017, over 100 PD subjects with a confirmed dopaminergic deficit on FDOPA-PET have been included. Discussion DUPARC is the first study to combine data within, but not limited to, the non-motor domains of cognition, gastrointestinal function and vision in PD subjects over time. As a de novo PD cohort, with treatment naïve subjects at baseline, DUPARC provides a unique opportunity for biomarker discovery and validation without the possible confounding influences of dopaminergic medication. Trial registration NCT04180865; registered retrospectively, November 28th 2019.

Follow-up evaluation of motor and non-motor symptoms in essential tremor

2021 ◽  
Vol 429 ◽  
pp. 119507
Author(s):  
Luca Angelini ◽  
Alessandro De Biase ◽  
Giulia Paparella ◽  
Antonella Di Vita ◽  
Matteo Panfili ◽  
...  
Keyword(s):  
Essential Tremor ◽  
Motor Symptoms ◽  
Non Motor Symptoms

Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients

2012 ◽  
Vol 84 (1) ◽  
pp. 14-17 ◽  
Author(s):  
Roberto Erro ◽  
Marina Picillo ◽  
Carmine Vitale ◽  
Marianna Amboni ◽  
Marcello Moccia ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Symptoms ◽  
Follow Up Study ◽  
Non Motor Symptoms ◽  
Early Parkinson’S Disease

scholarly journals Change in Non-motor Symptoms in Parkinson’s Disease and Essential Tremor Patients: A One-year Follow-up Study

2014 ◽  
Vol 4 (0) ◽  
pp. 216 ◽  
Author(s):  
Maurizio Giorelli ◽  
Junia Bagnoli ◽  
Luigi Consiglio ◽  
Pasquale Difazio ◽  
Daniela Zizza ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Essential Tremor ◽  
Motor Symptoms ◽  
Follow Up Study ◽  
One Year ◽  
Non Motor Symptoms
Sign in / Sign up

Export Citation Format

Share Document